The method of normalization of the functional status of platelets

 

(57) Abstract:

The invention relates to medicine, and is intended for normalization of the functional status of platelets in infectious pathology. Influence of laser radiation with a wavelength of 0.63 Ám in the blood within 5 min the rate of 5 - 6 sessions intravenously at a power of 1 mW or transcutaneous at a power of 10 mW. The method allows to normalize the functional status of platelets in infectious pathology. 2 Il.

The invention relates to infectious diseases, and is intended for normalization of hemostasis, and in particular the functional activity of platelets with low-intensity laser radiation (NEELY).

In the pathogenesis of many infectious diseases are also important abnormalities in the hemostatic system. In viral hepatitis (SH) clinical manifestations of discoordination the gemokoagulyatsii can vary from mild to massive bleeding (Bluher A. F., I. Novitsky N. Viral hepatitis, Riga, - 1988. - 412 S.; J. H. Joist Hemostasis and Trombosis: Basic principles and clinical practis. - 1987. - P. 861-872; Carr J. M. Hepatology. - 1989. - V. 10. - N 1. - P. pp. 103 -- 110.). The functioning of this multicomponent system is determined not only by the state PLAZMENNOGO the B. And, Barkagan H. C. Hematology and Transfusiology. - 1991. - N 1. - S. 22; Greaves M. Platelet function test in the assessment of antithrombotic agents. Br. J. Clin. Pharmacol. - 1990. - V. 30. - N 2. - P. 175-176).

There is a method of correction of hemostasis in patients with acute viral hepatitis during treatment with plasmapheresis. (Makhrova M. B. abnormalities in the hemostatic system in patients with acute viral hepatitis and their correction during treatment with plasmapheresis: author. dis. Kida. honey Sciences. - M., 1997. - S. 18.)

The disadvantage of analog is invasive and expensive procedure, as well as the uniformity of response of platelet hemostasis to conduct plasmapheresis, which consists in significantly less platelet aggregation.

The known method effects on hemostasis. (Karavaeva M. S. Clinical and pathogenetic value of the impaired cellular hemostasis in viral hepatitis: author. dis. Kida. the honey. Sciences. - M., 1998. - S. 17). The author showed that in viral hepatitis magnetic-infrared laser with a wavelength of 0.89 microns apparatus "MILTA" on the area of projection of the liver in 8-10 sessions with a duration of 6-12 min exerted a predominant influence on erythrocyte link microcirculatory homeostasis. This method is adopted for the nearest equivalent.

Not the result of a stand-alone application of radiation only to the area of the projection of the liver.

In the pathogenesis of infectious diseases, including viral hepatitis, in the development of hemocoagulation disorders are crucial violations of the functional activity of platelets: their aggregation and secretion ability. (Kuznetsov, E. N. The state of gemokoagulyatsii and fibrinolysis in patients with acute viral hepatitis and the effects of some therapies: author. dis. Kida. the honey. Sciences. - M., 1984. - S. 22.)

The functional activity of platelets correlates with the severity and stage of the disease as in bacterial (Polyakov, A. M. the Role of platelet hemostasis in the Genesis of hemocoagulation disorders in patients with bacterial infections: author. dis. Prof. the honey. Sciences. - M., 2000. - S. 38) and viral infections (Kravchenko A. C. Clinical and pathogenetic features of disorders of the hemostatic system in patients with HIV infection: author. dis. Prof. the honey. Sciences. - M., 1998. - S. 42-43). According to C. E. Kazulin (Functional activity of platelets in viral hepatitis and hemorrhagic syndrome: author. dis. Kida. the honey. Sciences. Bitter, 1983. - S. 10-11, 21) patients with ovhv on the background thrombocytopenia change in the functional activity of platelets is of a mixed nature: mild form ockene aggregation ability, while severe hepatitis is accompanied by inhibition of the dynamic function of blood platelets.

The technical result of the invention is the restoration of violated properties of platelets in infectious pathology, particularly in viral hepatitis C.

The technical result is achieved due to the normalizing effects of low-intensity laser radiation on the functional activity of platelets with intravenous or venous way of its application. Thus, when expressed gipokoagulyatsii and of consumption coagulopathy occurring in viral hepatitis, and consequently the possibilities of development of bleeding, laser radiation promotes the aggregation of platelets, thereby preventing one of the most serious complications of this disease. Conversely, when there is increased functional activity of platelets, low-intensity laser irradiation reduces their aggregation ability, indicating a normalizing influence of laser irradiation on platelet hemostasis. This is achieved either through a direct effect on platelets with intravascular hcpa is discontenting infrared laser radiation on cutaneous afferents. - Questions of balneology, physiotherapy and physical therapy. - 1995. - N 5. - S. 10-13.) showed that the "target" of the action of low-intensity laser radiation in the skin of rats are not receptor membrane mechanoreceptors and their preterminal elektrovojvodina areas. Along with the local reactions of the surface tissue of the propagation of laser radiation as the mechanism of axon-reflex, and by segmental-one metameric links and other generalized reaction of the entire organism (activation of the endocrine glands, haematopoiesis, reparative processes in nerve, muscle, bone and other tissues). This may explain that we receive therapeutic effect of transcutaneous action of low-intensity laser radiation.

The method is as follows. Low-intensity laser radiation of a wavelength of 0.63 Ám affect blood intravenously with output power of a single light guide 1 mW for 5 minutes (dose of laser radiation for 1 session of 300 MJ) or transcutaneous power of 10 mW on the projection of the cubital vein with exposure time 5 minutes (dose of laser radiation for 1 session of 30 MJ) number of 5-6 sessions.

Example 1. Patient X., 24 years old, was admitted on the 15th day of bolezn the awn and bitter taste in the mouth, poor sleep, jaundice, dark urine.

On the basis of gradual onset of the disease with predzheltushnogo period on the mixed variant (artrologicheskoy and astheno-vegetative), the emergence of hemorrhagic rash on the lower extremities and abdomen, dark urine and jaundice, data epidamnus (abortion six months before the disease), objective (increased liver 3-4 cm below the costal arch and spleen) and laboratory tests (increase in liver enzymes: ALT - 1024 units (rule 50), ACT - 1490 units (rule 50), bilirubin - 171,8 Ámol/l (normal 20 Ámol/l); the presence of HbsAg) diagnosed with acute viral hepatitis In icteric form.

Given the pronounced effects of intoxication, in addition to conventional therapy (intravenous infusion 5% glucose solution, antispasmodics and vitamins) that are assigned to laser therapy apparatus "Azor 2K" intravenous single fiber with output power of 1 mW, a wavelength of 0.63 Ám for 5 minutes in an amount of 5 sessions. Appetite and sleep recovered after 3 treatments, the headache disappeared after the 3rd, weakness after the 4th session. ALT activity decreased in 2 times with 1024 units to 674 units, bilirubin - 172 Ámol/l to 140 Ámol/l after the 5th treatment.

Functional sostojba diphosphate and its reversal. /Nature. - 1962. - Vol. 194. - N 4832. - P. 927-929). As inducer of aggregation used ADP at concentrations of 210-5M and 210-6M ("Reanal", Hungary). The original platelet aggregation 0.6%, and after 5 session it had risen to 45%, which indicates the normalizing effects of intravascular low level laser radiation (Fig. 1 top).

Thus, endovenous laser therapy (5 sessions contributed to the restoration of reduced functional activity of platelets and prevent possible bleeding (the presence of hemorrhagic rash on the abdomen and lower extremities) and improved the clinical course of acute viral hepatitis.

Example 2. Patient K. , aged 47, arrived on the 28th day of the disease, day 6 of jaundice in the state of moderate severity with complaints of severe weakness, dizziness, decreased appetite, jaundice.

Medical history: has been sick since October 8, when I had nausea, headache, joint pain, temperature 37,2. From October 20 - dark urine, October 22 - icteric staining of the sclera and skin, agalychnis feces, October 24, bloody crusts in the nasal cavity.

Epidamnus: In August 1999, the operation was performed on the occasion of the rupture of the Achilles sukhogorskaya rash. Peripheral lymph nodes are not enlarged, no edema. In the lungs vesicular breathing, wheezing no. Heart sounds clean, rhythmic. Pulse 60 beats./min, BP - 90/60 mm RT.article Tongue dry, lined with yellow-white bloom. The abdomen is soft, slightly swollen, painful in the epigastrium and right hypochondrium. The liver stands out from the edge of a costal arch on 5-6 cm below the costal arch, the average density is palpable spleen. Chair holicky, dark urine. Clear consciousness. Adequate, oriented in time and place. Meningeal and no focal symptoms. Signs of acute hepatic encephalopathy (PO) no.

Diagnosed with acute viral hepatitis on the basis of gradual onset of the disease with predzheltushnogo period by mixed type (artrologicheskoy and dyspepsia), the appearance of jaundice, dark urine, hepatomegaly, data epidamnus (surgery 3 months prior to illness), and laboratory tests (total bilirubin at admission - 216 Ámol/l, ALT - 2255 unit, ACT - 2055 units, the presence of serum HBsAg and Hbcor IgM).

Assigned to conventional therapy: diet (table 5), bed rest, intravenous drip infusion of glucose 5% solution, gemodeza up to 2 liters per day, symptomatic Ter the of and on the 4th day of hospital stay day 8 of jaundice assigned to laser therapy apparatus "Azor-K a wavelength of 0.63 Ám output power of the light guide 10 mW contact-compression method nadonna on the elbow vascular bundle within 5 minutes After 2 sessions LT condition improved: reduced weakness, which disappeared after the 6th session LT. Dizziness and headache decreased after 1 session and were stopped after the 2nd, sleep was normalized after the 2nd procedure. After the 5th session venous laser therapy bilirubin decreased from 216 Ámol/l to 54.4 mmol/l, ALT with 2255 unit to 262, ACT - 2055% to 226 units held 6 sessions transcutaneous laser therapy.

Before treatment, the patient was observed pronounced giperagregatsiyu platelet - 193%. After 1 session, it has decreased in 2 times after a 5 - normalized, (Fig. 2, bottom). According to thromboelastogram can be assumed that the patient was latent flowing form of DIC, indicating severe viral hepatitis. Using venous laser therapy, it failed to arrest.

The patient was discharged in good condition on day 52 of the disease 30 day jaundice without residual effects. The patient was in the hospital 25 days.

The method can be applied to any infectious pathology involving violation of system gemokoagulyatsii.

Thus, the proposed method allows to achieve normalization of the functional properties of platelet-u b any 0.63 Ám with direct effects on blood intravascular way a single fiber with a power output of 1 mW or transcutaneous contact method 10 mW within 5 minutes of 5 to 6 sessions.

The method of normalization of the functional status of platelets in infectious pathology, including low-intensity laser therapy, characterized in that the impact of exercise on blood with a wavelength of 0.63 Ám for 5 min the rate of 5 - 6 sessions intravenously at a power of 1 mW or transcutaneous at a power of 10 mW.

 

Same patents:

The invention relates to medical equipment and can be used in the apparatus for non-invasive therapeutic effects of laser radiation on the pathologic lesion

The invention relates to medicine, in particular to the treatment of ischemic heart disease

The invention relates to medicine, in particular to physiotherapy

The invention relates to medicine, namely to methods for treating electromagnetic radiation

The invention relates to medicine, namely to methods of treatment of trophic ulcers of low-intensity laser radiation
The invention relates to medicine, namely to dermatology
The invention relates to urology and is intended to be a comprehensive treatment of chronic urethritis, urogenital infections caused
The invention relates to medicine, namely to the rehabilitation of hemodynamic disturbances associated with physical activity in overload mode
The invention relates to urology and is intended for the integrated treatment endourethral warts

FIELD: medicine.

SUBSTANCE: method involves introducing 0.1-0.3 ml of photosensitizing gel preliminarily activated with laser radiation, after having removed neovascular membrane. The photosensitizing gel is based on a viscoelastic of hyaluronic acid containing khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-2% by mass. The photosensitizing gel is in vitro activated with laser radiation having wavelength of 661-666 nm during 3-10 min with total radiation dose being equal to 100-600 J/cm2. The gel is introduced immediately after being activated. To compress the retina, vitreous cavity is filled with perfluororganic compound or air to be further substituted with silicon oil. The operation is ended with placing sutures on sclerotomy and conjunctiva areas. Compounds like chealon, viscoate or hyatulon are used as viscoelastic based on hyaluronic acid. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity.

EFFECT: excluded recurrences of surgically removed neovascular membrane and development of proliferative retinopathy and retina detachment; retained vision function.

3 cl, 5 dwg

FIELD: medicine.

SUBSTANCE: method involves making incision in conjunctiva and Tenon's capsule of 3-4 mm in size in choroid hemangioma projection to sclera 3-4 mm far from limb. Tunnel is built between sclera and Tenon's capsule to extrasclerally introduce flexible polymer magnetolaser implant through the tunnel to the place, the choroid hemangioma is localized, after performing transscleral diaphanoscopic adjustment of choroid hemangioma localization and size, under visual control using guidance beam. The implant has permanent ring-shaped magnet in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 2-3 mTesla units intensity. It is arranged with its north pole turned towards the choroid hemangioma so that extrascleral implant laser radiator disposition. The other end of the implant is sutured to sclera 5-6 mm far from the limb with two interrupted sutures through prefabricated openings. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. 0.1-1% khlorin solution is injected in intravenous bolus dose of 0.8-1.1 mg/kg as photosensitizer and visual control of choroid hemangioma cells fluorescence and fluorescent diagnosis methods are applied. After saturating choroid hemangioma with the photosensitizer to maximum level, transscleral choroid hemangioma laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm with total radiation dose being equal to 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the intraocular neoplasm, repeated laser irradiation of the choroid hemangioma is carried out with radiation dose of 30-60 J/cm2.

EFFECT: enhanced effectiveness of treatment.

4 cl

FIELD: medicine.

SUBSTANCE: method involves creating tunnel between sclera and Tenon's capsule in intraocular neoplasm projection. Intraocular neoplasm localization and size is adjusted by applying transscleral diaphanoscopic examination method. 0.1-0.3 ml of photosensitizing gel based on viscoelastic of hyaluronic acid, selected from group containing chealon, viscoate or hyatulon, is transsclerally introduced into intraocular neoplasm structure using special purpose needle in dosed manner. The photosensitizing gel contains khlorin, selected from group containing photolon, radachlorine or photoditazine in the amount of 0.1-1% by mass. Flexible polymer magnetolaser implant is extrasclerally introduced into the built tunnel in intraocular neoplasm projection zone under visual control using guidance beam. The implant has permanent ring-shaped magnet axially magnetized and producing permanent magnetic field of 3-4 mTesla units intensity, in the center of which a short focus scattering lens of laser radiator is fixed. The lens is connected to light guide in soft flexible envelope. The implant is arranged with its north pole turned towards the intraocular neoplasm so that implant laser radiator lens is extrasclerally arranged in intraocular neoplasm projection zone. The implant light guide is sutured to sclera 5-6 mm far from the limb with single interrupted suture. The implant is covered with conjunctiva and relaxation sutures are placed over it. Light guide outlet is attached to temple using any known method. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transscleral intraocular neoplasm laser radiation treatment is carried out via laser light guide and implant lens using divergent laser radiation at wavelength of 661-666 nm. The treatment course being over, the flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, neodymium-iron-boron or samarium-iron-nitrogen. 0.1-1% khlorin solution as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is additionally intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg and repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2 15-20 min later during 30-90 s.

EFFECT: complete destruction of neoplasm; excluded its further growth.

4 cl

FIELD: medicine.

SUBSTANCE: method involves applying transscleral diaphanoscopic examination method for adjusting intraocular neoplasm localization and size. Rectangular scleral pocket is built 2/3 times as large as sclera thickness which base is turned from the limb. Several electrodes manufactured from a metal of platinum group are introduced into intraocular neoplasm structure via the built scleral pocket. Next to it, intraocular neoplasm electrochemical destruction is carried out in changing electrodes polarity with current intensity of 100 mA during 1-10 min, and the electrodes are removed. Superficial scleral flap is returned to its place and fixed with interrupted sutures. 0.1-2% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, transpupillary laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2. the operation is ended with placing sutures on conjunctiva. Platinum, iridium or rhodium are used as the metals of platinum group. The number of electrodes is equal to 4-8. 0.1-1% khlorin solution, selected from group containing photolon, radachlorine or photoditazine, is additionally repeatedly intravenously introduced in 2-3 days at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells is carried out by applying fluorescence and fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, repeated laser irradiation of the intraocular neoplasm is carried out with radiation dose of 30-45 J/cm2.

EFFECT: complete destruction of neoplasm; excluded tumor recurrence; reduced risk of tumor cells dissemination.

3 cl, 3 dwg

FIELD: medicine.

SUBSTANCE: the present innovation deals with treating vascular cutaneous neoplasms, such as nevus flammeus and gemangiomas. Light-thermal impact at energy ranged 39-47 J/sq. cm should be performed in two stages, and between them, 2-3 wk after the onset of vascular resistance at the first stage one should perform beta-therapy daily for 2-3 d at single dosage being 20 g. Then, 3 wk later it is necessary to conduct the second stage of light-thermal impact by starting at energy value being 42 J/sq. cm, not less. The method enables to shorten therapy terms due to applying combined method to affect vascular cutaneous neoplasms.

EFFECT: higher therapeutic and cosmetic effect.

1 ex

FIELD: medicine.

SUBSTANCE: method involves intravitreously introducing two electrodes into intraocular neoplasm after carrying out vitrectomy and retinotomy to expose the intraocular neoplasm. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with current intensity of 100 mA during 1-10 min or 10 mA during 10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2.The transformed retina and tumor destruction products are intravitreally removed. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. Another embodiment of the invention involves adjusting position and size of the intraocular neoplasm in trans-scleral diaphanoscopic way. Rectangular scleral pocket is built above the intraocular neoplasm to 2/3 of sclera thickness with its base turned away from limb. Several electrodes are introduced into intraocular neoplasm structure via the built bed. The electrodes are manufactured from platinum group metal. Electrochemical destruction is carried out with the same current intensity in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. Superficial scleral flat is returned to its place and fixed with interrupted sutures. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg after having carried out vitrectomy and retinotomy. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous laser radiation is carried out in parallel light beam of wavelength equal to 661-666 nm is applied at a dose of 30-120 J/cm2. The transformed retina and tumor destruction products are intravitreally removed using vitreotome. Boundary-making endolasercoagulation of retinotomy area is carried out after having smoothed and compressed retina with perfluororganic compound. The operation is finished with placing sutures on sclerotomy and conjunctiva. Platinum, iridium or rhodium are used as the platinum group metals. The number of electrodes is equal to 4-8.

EFFECT: reduced risk of metastasizing.

4 cl, 13 dwg

FIELD: medicine.

SUBSTANCE: method involves building tunnel to posterior eyeball pole in inferoexterior and superexterior quadrants. The tunnel is used for implanting flexible polymer magnetolaser implant to the place, the subretinal neovascular membrane is localized. The implant has a permanent magnet shaped as a cut ring and is provided with drug delivery system and a short focus scattering lens of laser radiator connected to light guide. The permanent implant magnet is axially magnetized and produces permanent magnetic field of 5-7 mTesla units intensity. It is arranged with its north pole turned towards sclera at the place of the subretinal neovascular membrane projection with extrascleral arrangement of laser radiator lens membrane being provided in the subretinal neovascular membrane projection area. The other implant end is sutured to sclera 5-6 mm far from the limb via holes made in advance. The implant is covered with conjunctiva and retention sutures are placed thereon. Light guide and drug supply system lead is attached to temple with any known method applied. Drugs are supplied via the implant drug supply system in retrobulbary way in any order. Triombrast is given in the amount of 0,4-0,6 ml and dexamethasone or dexone in the amount of 0,4-0,6 ml during 3-4 days every 12 h. 0.1-1% aqueous solution of khlorin is intravenously introduced at the third-fourth day after setting the implant as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, at a bolus dose of 0.8-1.1 mg/kg. Visual control of subretinal neovascular membrane cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the subretinal neovascular membrane with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at general dose of 30-120 J/cm2. The flexible polymer magnetolaser implant is removed and sutures are placed on conjunctiva. Permanent magnet of the flexible polymer magnetolaser implant is manufactured from samarium-cobalt, samarium-iron-nitrogen or neodymium-iron-boron system material. The photosensitizer is repeatedly intravenously introduced at the same dose in 2-3 days after the first laser radiation treatment. Visual intraocular neoplasm cells fluorescence control is carried out using fluorescent diagnosis techniques. Maximum level of saturation with the photosensitizer being achieved in the subretinal neovascular membrane via laser light guide and implant lens, repeated laser irradiation of the subretinal neovascular membrane is carried out with radiation dose of 30-60 J/cm2.

EFFECT: accelerated subretinal edema and hemorrhages resorption; regression and obliteration of the subretinal neovascular membrane; prolonged vision function stabilization.

6 cl

FIELD: medicine.

SUBSTANCE: method involves filling vitreous cavity with perfluororganic compound. Two electrodes manufactured from platinum group metal are intravitreally, transretinally introduced into intraocular neoplasm. Electrochemical destruction is carried out with current intensity of 10-100 mA during 1-10 min in changing electrodes polarity and their position in the intraocular neoplasm space, and the electrodes are removed. 0.1-1% aqueous solution of khlorin as photosensitizer, selected from group containing photolon, radachlorine or photoditazine, is intravenously introduced at a dose of 0.8-1.1 mg/kg. Visual control of intraocular neoplasm cells fluorescence is carried out by applying fluorescent diagnosis methods. After saturating the intraocular neoplasm with the photosensitizer to maximum saturation level, intravitreous, transretinal laser radiation of 661-666 nm large wavelength is applied at a dose of 30-120 J/cm2 in perfluororganic compound medium. The transformed retina and tumor destruction products are intravitreally removed with perfluororganic compound volume being compensated with its additional introduction. Boundary-making endolasercoagulation of retinotomy area is carried out. The perfluororganic compound is substituted with silicon oil. The operation is ended in placing sutures over sclerotmy areas and over conjunctiva. Perfluormetylcyclohexylperidin, perfluortributylamine or perfluorpolyester or like are used as the perfluororganic compound for filling vitreous cavity. Platinum, iridium or rhodium are used as the platinum group metals.

EFFECT: complete destruction of neoplasm; reduced dissemination risk.

6 cl, 12 dwg

FIELD: medicine, applicable for stopping of pains of various nature.

SUBSTANCE: the device has a quantum-mechanical oscillator located in a casing, magnet, vessel for medicinal agent and a hollow cylinder. The magnet is installed between the oscillator and the vessel. Positioned in the vessel is a hollow cylinder having through holes on its surface.

EFFECT: quick and absolute anestesia.

2 ex, 1 dwg

FIELD: medicine.

SUBSTANCE: method involves administering laser radiation therapy once a day using low intensity pulsating radiation of wavelength equal to 890nmand power density of 0.03 mW/cm2. Injured organ projection to frontal abdominal wall is exposed to radiation at the first laser therapy stage in two fields acting upon each field for 2 min with radiation pulse succession frequency equal to 80 Hz in applying stable contact-type method. Total treatment dose on two fields is equal to 0.008 J/cm2. The second laser therapy stage begins immediately after having finished the first one in applying radiation along the large intestine path using labile contact-type method in a way that radiation pulse succession frequency equal to 80 Hz is applied first during 1 min and then frequencies of 600, 150 and 300 Hz are applied also during 1 min, respectively. Total treatment dose is equal to 0.032 J/cm2 at the second stage. Total treatment dose is equal to 0.04 J/cm2 at both stages.

EFFECT: enhanced effectiveness in inhibiting dysbacteriosis; reduced frequency of postoperative complications.

Up!